acr-368
Generic: prexasertib·Code: ACR-368
acr-368: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | Phase 2 |
FDA Decisions
FDA_MeetingFDA Type B meeting earlier in 2025 provided feedback that was incorporated into the Phase 3 protocol submission for ACR-368 with anti-PD-1; no further FDA feedback received.(ACRV)
Frequently asked questions
Who is developing acr-368?
acr-368 is being developed by Acrivon Therapeutics, Inc..
What is acr-368's latest FDA decision?
The most recent tracked FDA decision for acr-368 is FDA_Meeting for FDA Type B meeting earlier in 2025 provided feedback that was incorporated into the Phase 3 protocol submission for ACR-368 with anti-PD-1; no further FDA feedback received..
Get deeper analysis on acr-368
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis